A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections

被引：36
作者：
Adedoyin, A
Swenson, CE
Bolcsak, LE
Hellmann, A
Radowska, D
Horwith, G
Janoff, AS
Branch, RA
机构：
[1] Univ Pittsburgh, Med Ctr, Ctr Clin Pharmacol, Pittsburgh, PA 15213 USA
[2] Liposome Co Inc, Princeton, NJ USA
[3] Med Univ Gdansk, Dept Hematol, Gdansk, Poland
[4] Prov Hosp Infect Dis, Gdansk, Poland
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 10期
关键词：
D O I：
10.1128/AAC.44.10.2900-2902.2000
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
This study describes a pharmacokinetic evaluation of amphotericin B (AMB) lipid complex injection (ABLC or Abelcet) in 17 patients with systemic fungal infection administered 5 mg/kg of body weight/day by infusion for 10 to 17 days. The results showed that AMB exhibited multiexponential disposition with high clearance, large volume of distribution at steady state, and long apparent elimination half-life but no evidence of accumulation in the blood after multiple daily doses. The results confirm previous observations and further reinforce the suggestion that ABLC may exist as a depot in the tissues from which free AMB is slowly released to limit exposure.
引用
收藏
页码：2900 / 2902
页数：3
相关论文
共 16 条
[1]   Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): Combined experience from phase I and phase II studies [J].
Adedoyin, A ;
Bernardo, JF ;
Swenson, CE ;
Bolsack, LE ;
Horwith, G ;
DeWit, S ;
Kelly, E ;
Klasterksy, J ;
Sculier, JP ;
DeValeriola, D ;
Anaissie, E ;
LopezBerestein, G ;
LlanosCuentas, A ;
Boyle, A ;
Branch, RA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2201-2208
[2]  
Adler-Moore J.P., 1993, Journal of Liposome Research, V3, P429, DOI DOI 10.3109/08982109309150729
[3]   Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats [J].
Bhamra, R ;
SAAd, A ;
Bolcsak, LE ;
Janoff, AS ;
Swenson, CE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :886-892
[4]  
GALLIS HA, 1990, REV INFECT DIS, V12, P27
[5]   AMPHOTERICIN-B AND ITS DELIVERY BY LIPOSOMAL AND LIPID FORMULATIONS [J].
GATES, C ;
PINNEY, RJ .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1993, 18 (03) :147-153
[6]  
Guo LSS, 1993, J LIPOSOME RES, V3, P473
[7]   LIPOSOMAL AND LIPID FORMULATIONS OF AMPHOTERICIN-B - CLINICAL PHARMACOKINETICS [J].
JANKNEGT, R ;
DEMARIE, S ;
BAKKERWOUDENBERG, IAJM ;
CROMMELIN, DJA .
CLINICAL PHARMACOKINETICS, 1992, 23 (04) :279-291
[8]   UNUSUAL LIPID STRUCTURES SELECTIVELY REDUCE THE TOXICITY OF AMPHOTERICIN-B [J].
JANOFF, AS ;
BONI, LT ;
POPESCU, MC ;
MINCHEY, SR ;
CULLIS, PR ;
MADDEN, TD ;
TARASCHI, T ;
GRUNER, SM ;
SHYAMSUNDER, E ;
TATE, MW ;
MENDELSOHN, R ;
BONNER, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (16) :6122-6126
[9]  
Janoff SA, 1993, J LIPOSOME RES, V3, P451
[10]   COMPARATIVE SAFETY, TOLERANCE, AND PHARMACOKINETICS OF AMPHOTERICIN-B LIPID COMPLEX AND AMPHOTERICIN-B DEOXYCHOLATE IN HEALTHY MALE-VOLUNTEERS [J].
KAN, VL ;
BENNETT, JE ;
AMANTEA, MA ;
SMOLSKIS, MC ;
MCMANUS, E ;
GRASELA, DM ;
SHERMAN, JW .
JOURNAL OF INFECTIOUS DISEASES, 1991, 164 (02) :418-421
12